Manuel Emiliano Quiroga Garza

Manuel Emiliano Quiroga Garza

Auto-generated profile, based on publicly available information

Manuel Emiliano Quiroga Garza

University of Miami

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2024 in The Ocular Surface
Verified
Journal Article
Closed access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
MSMatias Soifer
Matias Soifer
ZZZane Z. Zemborain
Zane Z. Zemborain
NANadim S. Azar
Nadim S. Azar
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
VPVictor L. Perez
Victor L. Perez

25 February 2022 in Disability and Health Journal
Verified
Journal Article
Closed access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
SRSylvia de la Rosa-Pacheco
Sylvia de la Rosa-Pacheco
JHJulio C. Hernández-Camarena
Julio C. Hernández-Camarena
LGLucas A. Garza-Garza
Lucas A. Garza-Garza
ODOsvaldo Davila-Cavazos
Osvaldo Davila-Cavazos
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia

6 March 2024 in Ophthalmology
Verified
Journal Article
Closed access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
MCMaria F. Colorado-Zavala
Maria F. Colorado-Zavala
EREugenia M. Ramos-Dávila
Eugenia M. Ramos-Dávila
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
NANadim S. Azar
Nadim S. Azar
VPVictor L Perez
Victor L Perez

13 August 2022 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
JAJimena Alamillo-Velazquez
Jimena Alamillo-Velazquez
GMGustavo Ortiz Morales
Gustavo Ortiz Morales
LGLucas A. Garza-Garza
Lucas A. Garza-Garza
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia

3 July 2025 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
AKAli Khodor
Ali Khodor
JCJonathan T. Caranfa
Jonathan T. Caranfa
TNTavish Nanda
Tavish Nanda
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
AWAndre J. Witkin
Andre J. Witkin
Introduction To evaluate the outcomes of intravitreal faricimab (IVF; Vabysmo®) in previously treated patients with wet age-related macular degeneration (wAMD), focusing on best available visual acuity (BAVA), central subfield thickness (CST), injection interval, complications, fluid resolution, and reversion rates to prior therapies. Methods The PubMed, Embase, and Google Scholar databases were searched for studies reporting outcomes of treatments for previously treated cases of wAMD. Mean differences (MD) with 95% confidence intervals (CI) were used to compute the effect size of the change in outcomes. Results A total of 29 studies with 2070 patients (1003 women, mean age 78.9 years) and 2128 eyes were included. BAVA and CST were reported in 28 studies, fluid status in 21, injection interval in 14, and reversion rates in 6. Pooled analysis showed significant but modest improvement in BAVA when IVF was given for > 6 months (MD = −0.026 LogMAR, p < 0.05) but not at earlier follow-ups. A similar trend was noted with injection interval extension when IVF was given beyond 6 months (MD = +2.1 weeks, p < 0.05). CST reduction was observed at all time points (overall MD = −37.7 μm, p < 0.05). Complication rates were reported in nine studies, with an overall rate of 1.2%, including retinal pigment epithelium tear, intraocular inflammation, endophthalmitis, and subretinal hemorrhage. Reversion to prior or other anti-vascular endothelial growth factor (anti-VEGF) therapy was reported in six studies, occurring in 23% of eyes. Conclusions We reported the outcomes of utilizing IVF in previously treated cases of wAMD. IVF showed a significant improvement in CST at all time points and in the extension of injection interval. Visual outcomes remained unchanged when followed for less than 6 months but improved significantly but modestly when followed for more than 6 months. Switching to intravitreal faricimab may be a useful treatment option for previously treated patients with wAMD, with a goal of reducing treatment burden and improving treatment efficacy.

2 November 2024 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
MHMonica I. Herrera-Rodriguez
Monica I. Herrera-Rodriguez
JMJazmin A. Mendoza-Pallares
Jazmin A. Mendoza-Pallares
NRNatalia Reyes-Godinez
Natalia Reyes-Godinez
VTVeronica E. Tamez-Tamez
Veronica E. Tamez-Tamez
ARAlejandro Rodriguez-Garcia
Alejandro Rodriguez-Garcia
Introduction The needs of family caregivers providing care to relatives with visual impairment are often dismissed, leading to caregiver burden. The Zarit Burden Interview (ZBI) can measure the caregiver burden of caring for a family member with vision impairment. The purpose of this study is to validate the ZBI in Mexican family caregivers of patients with visual impairment. Methods The ZBI was applied to 137 family caregivers of patients with visual acuity ≤ 20/200 in the best eye for ≥ 6 months. The ZBI’s reliability was determined using Cronbach’s α and the factor structure using exploratory factor analysis (EFA, principal axis factoring with promax rotation). Items with loadings < 0.400 were eliminated. Retained factors were determined using the scree test and Horn’s parallel analysis (95% CI). Associations between burden factors and other variables were evaluated with descriptive and inferential statistics. Results Mean ZBI score was 26.2 ± 13.1, and internal consistency was high (α = 0.871). EFA yielded four factors: (1) embarrassment and frustration, (2) self-efficacy expectations, (3) interference in personal relationships, and (4) personal strain. The α values ranged from 0.649 to 0.812. Spousal caregivers had significantly higher scores (factors 1, 2, and 4), whereas adult children had less scores (factor 3). There was a significant positive correlation between hours of daily caregiving and factors 2 (r = 0.350) and 3 (r = 0.388). A worse degree of visual impairment was associated with higher mean factor scores in all factors. Conclusions The ZBI is a valid instrument to detect burden in Mexican caregivers of patients with visual impairment. We identified a four-factor structure that improved our understanding of the ZBI’s underlying constructs. Interventions targeting specific types of burden are warranted.